ストックスクリーナーアプリを入手
2.6854
4.47%
0.1154
前日終値:
$2.57
開ける：
$2.56
24時間の取引高:
3.40M
Relative Volume:
0.38
時価総額：
$2.95B
収益：
$1.31M
当期純損益:
$-597.65M
株価収益率:
-2.7685
EPS:
-0.97
ネットキャッシュフロー:
$-425.62M
1週間 パフォーマンス:
-2.72%
1か月 パフォーマンス:
+0.56%
6か月 パフォーマンス:
+4.47%
1年 パフォーマンス:
-56.55%
1日の値動き範囲:
$2.55
$2.77
1週間の範囲:
$2.50
$2.82
52週間の値動き範囲:
$1.83
$7.48
Immunitybio Inc Stock (IBRX) Company Profile
IBRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
2.685 | 2.95B | 1.31M | -597.65M | -425.62M | -0.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.80 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
549.03 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.39 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
550.75 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
243.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-20 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2025-03-06 | 開始されました | H.C. Wainwright | Buy |
| 2025-01-10 | 開始されました | BTIG Research | Buy |
| 2023-05-12 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-08-03 | 開始されました | Jefferies | Buy |
Immunitybio Inc (IBRX) 最新ニュース
ImmunityBio's $10.5M Investor Deal Gets Final OK - Law360
ImmunityBio Gets Final OK for $10.5 Million Investor Settlement - Bloomberg Law News
ImmunityBio’s ANKTIVA & FDA Expanded Access: Transforming bladder cancer treatment - pharmaphorum
As Public Cancer Funding Wavers, Oncology's Brightest Breakthroughs Are Coming From Industry - newswire.ca
ImmunityBio: Lymphopenia Opportunity Could Provoke Short Squeeze (NASDAQ:IBRX) - Seeking Alpha
ImmunityBio (IBRX) Jumps 18% on Anktiva Access Expansion - MSN
15 Stocks That Stole The Show Last Week - Insider Monkey
Why ImmunityBio, Inc. (IBRX) Surged On Thursday - MSN
Deadline to Claim Your Payout from the $10.5M ImmunityBio Settlement Is in 1 Month - TradingView
Why ImmunityBio, Inc. (IBRX) Skyrocketed Today - Yahoo Finance
H.C. Wainwright maintains buy rating on ImmunityBio stock after FDA milestones - Investing.com Nigeria
ImmunityBio (IBRX) Receives Reiterated Buy Rating from HC Wainwr - GuruFocus
ImmunityBio (IBRX) Receives Reiterated Buy Rating from HC Wainwright | IBRX Stock News - GuruFocus
Cancer Treatment Granted Lymphopenia Indication - Vax-Before-Travel
ImmunityBio receives FDA Expanded Access authorization for Cancer BioShield - Yahoo Finance
ASCO Report of Pioneering Treatment of Lymphopenia with Significant Overall Survival Benefit in Advanced Pancreatic Cancer - Bakersfield.com
ImmunityBio (IBRX) Receives Maintained Buy Rating from D. Boral Capital | IBRX Stock News - GuruFocus
FDA grants expanded access to ImmunityBio’s Anktiva for lymphopenia - Yahoo
FDA authorizes ANKTIVA for lymphopenia in cancer patients By Investing.com - Investing.com South Africa
ImmunityBio (IBRX) Gains FDA Nod for Cancer BioShield Platform - GuruFocus
ImmunityBio gets FDA expanded access authorization to treat lymphopenia with Anktiva - Seeking Alpha
ImmunityBio Receives Expanded FDA Authorization to Treat Lymphopenia in Cancer Patients - marketscreener.com
Immunitybio, Inc. Receives Fda Expanded Access Authorization for Landmark Treatment of Lymphopenia with Anktiva, the Cancer Bioshield? Platform, in Patients with Solid Tumors - marketscreener.com
ImmunityBio (IBRX) Gains FDA Approval for Expanded Access to Can - GuruFocus
FDA authorizes ANKTIVA for lymphopenia in cancer patients - Investing.com Australia
ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With ANKTIVA®, the Cancer BioShield™ Platform, in Patients With Solid Tumors - Placera.se
Immunitybio Receives FDA Expanded Access Authorization For Landmark Treatment Of Lymphopenia With Anktiva - marketscreener.com
ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With ANKTIVA - Business Wire
Advanced Pancreatic Cancer Pipeline 2025: Key Companies, MOA, - openPR.com
Advanced Pancreatic Cancer Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Incyte, AbbVie, Ability Pharma, AB Science, AstraZeneca, Eleison Pharma, ImmunityBio - The Globe and Mail
ImmunityBio: BioShield Platform Expands to Middle East and Other Important Updates - TradingView
ImmunityBio: Analyst Reaffirms $30 Price Target and Other Important Updates - TradingView
While Wall Street Naps, These 10 Stocks Run Wild - Insider Monkey
ImmunityBio (IBRX) Stock Rating and Price Target Update | IBRX S - GuruFocus
ImmunityBio (IBRX) Stock Rating and Price Target Update | IBRX Stock News - GuruFocus
Cancer BioShield Platform Comes to Saudi Arabia and the Middle East - Vax-Before-Travel
ImmunityBio, Saudi Arabia’s Ministry of Investment, KFSHRC, and KAIMRC Sign Strategic Memorandum of Understanding to Launch Cancer BioShield™ Platform in the Middle East - BioSpace
ImmunityBio Signs Agreement to Launch BioShield in Saudi Arabia, Middle East - marketscreener.com
Immunitybio, Inc. Signs Strategic Memorandum of Understanding to Launch Cancer Bioshield Platform in the Middle East - marketscreener.com
ImmunityBio, Saudi Arabia's Ministry of Investment, KFSHRC, and KAIMRC Sign Strategic Memorandum of Understanding - marketscreener.com
ImmunityBio (IBRX) Expands Cancer Treatment Platform to Middle E - GuruFocus
Natural Killer (NK)-Cell Lymphoma Market to Expand - openPR.com
Natural Killer (NK)-Cell Lymphoma Market to Expand Significantly by 2032, States DelveInsight Report | Innate Pharma, Nektar Therapeutics, ImmunityBio, CytoVac, Celularity - The Globe and Mail
ImmunityBio Board Settles Shareholders’ Cancer Therapy Lawsuit - Bloomberg Law News
Why ImmunityBio, Inc. (IBRX) Crashed Today - MSN
Piper Sandler Upgrades ImmunityBio (IBRX) to Overweight, Lifts PT - Insider Monkey
Piper Sandler Upgrades ImmunityBio (NASDAQ:IBRX) to Overweight - Defense World
Immunitybio Inc (IBRX) 財務データ
収益
当期純利益
現金流量
EPS
Immunitybio Inc (IBRX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| SOON-SHIONG PATRICK | See remarks |
Feb 22 '25 |
Option Exercise |
0.00 |
114,329 |
0 |
29,588,261 |
| Sachs David C. | Chief Financial Officer |
Feb 22 '25 |
Option Exercise |
0.00 |
40,650 |
0 |
241,480 |
| Adcock Richard | CEO & President |
Feb 22 '25 |
Option Exercise |
0.00 |
152,439 |
0 |
412,585 |
| Simon Barry J. | Director |
Feb 22 '25 |
Option Exercise |
0.00 |
15,243 |
0 |
3,249,024 |
| Simon Barry J. | Director |
Jan 22 '25 |
Option Exercise |
2.00 |
110,020 |
219,864 |
3,233,781 |
| Adcock Richard | CEO & President |
Dec 31 '24 |
Option Exercise |
0.00 |
34,483 |
0 |
277,621 |
| Sachs David C. | Chief Financial Officer |
Dec 31 '24 |
Option Exercise |
0.00 |
30,397 |
0 |
216,235 |
| LAUER REGAN J | Chief Accounting Officer |
Dec 15 '24 |
Option Exercise |
0.00 |
21,031 |
0 |
115,365 |
1.06%
0.54%
大文字化:
|
ボリューム (24 時間):